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Abstract 
Hepatitis C virus (HCV) infection is a prominent cause of 
chronic liver disease and may lead to serious complications 
such as liver failure and need for a transplant. The virus is 
transmitted via exposure to blood and is classified into vari-
ous genotypes based on genetic mutations in the virus. Cur-
rent treatment options for HCV infection are not effective in 
all patients, and there are limited options for patients in-
fected with a genotype other than genotype 1. Two new 
medications have been approved recently for treatment of 
HCV infection. Simeprevir (Olysio®) gained U.S. Food and 
Drug Administration (FDA) approval in November 2013, and 
sofosbuvir (Sovaldi®) was approved in December 2013. In-
formation from clinical trials with each of the medications 
supports their safety and efficacy in appropriate patient 
populations. The adverse effects are generally tolerable; 
however, for some patients, the adverse effects, drug interac-
tions and cost can be limiting factors. 
Introduction 
Hepatitis C virus is a blood-borne pathogen leading to long-
term hepatic complications if not properly treated.1 Current 
therapy for HCV includes ribavirin (RBV), peg-interferon alfa 
(PeglFN) and two options for protease inhibitors (boceprevir 
and telaprevir), which can only be used in one genotype of 
HCV infection.2-4 Two new medications were recently ap-
proved for treatment of chronic HCV infection: simeprevir 
(Olysio®) in November 2013 and sofosbuvir (Sovaldi®) in 
December 2013.s,6 These new medications can provide more 
treatment options to patients with different genotypes or for 
whom prior treatment with RBV and PeglFN was unsuccess-
fuJ.7,8 Safety and efficacy have been demonstrated in several 
clinical trials.9-12 The adverse reactions and cost of these 
medications are important factors to consider when deter-
mining treatment for HCV infection in a patient. 
Disease State Overview 
Hepatitis C infects approximately 170 million individuals 
worldwide, which has become both a public health and an 
economic issue.13 Being the most common blood-borne 
pathogen, the HCV is one of the leading causes of chronic 
liver disease and the third leading cause of death in patients 
with end stage renal disease,1.2 All individuals who are 
infected with HCV are at a greater risk for developing long-
term complications such as cirrhosis, liver failure and hepa-
tocellular carcinoma.14 
Hepatitis C virus is a single-stranded, positive RNA virus, 
which has a high rate of mutation, leading to therapy resis-
tance and immune system evasion.ls Presentation varies 
from patient to patient in that some patients may present 
with mild hepatitis or inflammation of the liver, while others 
experience scarring or even liver cancer.16 The first phase 
begins with HCV exposure which results in high viral titers 
being expressed in the blood. In this early stage, which typi-
cally lasts six to eight weeks, a T-cell mediated immune 
response is apparent in the absence of liver damage. The sec-
ond phase of HCV infection begins with the generation of 
HCV specific antibodies and T-cells. This phase is also charac-
terized by an increase in liver enzyme levels, which is evi-
dence of hepatocyte destruction. Phase three, which takes 
place 12 to 24 weeks after infection, shows variations in HCV 
viremia as well as decreasing capabilities of functional 
T-cells. Phase four, or 24 weeks post-infection, marks the end 
of the acute phase of the HCV infection as cellular immunity 
continues to evolve. 
The virus itself does not cause damage to the liver, but rather 
the response it elicits from the immune system causes 
healthy liver tissue to be replaced with scar tissue.10 Typi-
cally, the preferred treatment for HCV is PegIFN along with 
RBV, a nucleoside analogue, to which approximately 55 per-
cent of patients respond. For those patients who are non-
responders, few treatment options exist, which has led to 
further research and development of HCV medications. 
Treatment for HCV has evolved over the past years owing to 
advances in research and drug therapy.2 Treatment in the 
mid-1990s consisted of interferon monotherapy, which was 
injected three times a week for a total duration of six to 12 
months. In the late 1990s, RBV was added to interferon, 
which dramatically increased a patient's sustained virologic 
response (SVR). A sustained virologic response is defined as 
a lack of HCV in the blood after 24 weeks of treatment and 
remains the best indication of how successful therapy is in a 
patient.18 Therapy evolved once more to the current regimen 
of PegIFN in addition to RBV.2The ultimate goal of treatment 
in patients with HCV is to reach an SVR, as defined above. 
Currently, there is no vaccine to prevent HCV.19 
Genotyping plays an important role in determining treat-
ment for HCv.20 Currently, there are six clinically significant 
genotypes (1-6) identified for HCV, of which some are found 
to be more prevalent in different parts of the world. For ex-
ample, genotypes 1 through 3 are more common in the 
United States and Europe, genotype 4 is found most often in 
Egypt, and genotype 6 is more common in South Asia. Based 
on what genotype a person has, treatment and also response 
to treatment will differ. HCV genotyping is done to provide 
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the most effective therapy and to get the maximum response 
out of the medication prescribed. 
Overview of New Medications 
Two new medications have recently been approved for the 
treatment of chronic HCV infection.6 The first is simeprevir 
(Olysio®), approved Nov. 22, 2013.5 The second is sofosbuvir 
(Sovaldi®), approved Dec. 6, 2013. 
Simeprevir is a HCV NS3/4A protease inhibitor to be used in 
combination with Peg!FN and RBV to treat chronic HCV in-
fection in patients with genotype 1 HCV infection.7 The HCV 
NS3/4A protein is a serine protease that is essential in cleav-
ing the single HCV polyprotein precursor into the 10 individ-
ual proteins needed for HCV maturation and replication.21,22 
Inhibition of NS3/4A prevents the viral replication of HCv.21 
Simeprevir is the third HCV NS3/4A protease inhibitor to 
receive approval, with the previous two being boceprevir 
(Victrelis®) and telaprevir (Incivek®), each approved in 
2011.5 Simeprevir differs from the other two protease inhibi-
tors in that it is administered only once daily; however, all 
three protease inhibitors are only effective in genotype 1 
HCV infection and must be used with both Peg!FN and 
RBV.3.4.7 Simeprevir is a 150 mg capsule taken once daily 
with food.7 The treatment schedule is 12 weeks of simeprevir 
with Peg!FN and RBV for 24 or 48 weeks, depending on prior 
treatment status. 
Sofosbuvir is a NS5B polymerase inhibitor.8 The HCV protein 
NS5B is an RNA polymerase that transcribes viral RNA in 
order to produce HCV proteins.s,23 Sofosbuvir is a nucleotide 
prodrug that is converted in the liver to a uridine analog, 
which then inhibits the work of NS5B by incorporating into 
HCV RNA and acting as a chain terminator, thereby prevent-
ing the completion of viral replication. Sofosbuvir has shown 
efficacy in treating genotypes 1, 2, 3 and 4 HCV infection.a 
Sofosbuvir is a 400 mg tablet taken once daily without regard 
to food. Genotype of HCV infection determines treatment 
duration and PegIFN requirement. Genotype 1 is treated with 
sofosbuvir plus Peg!FN and RBV for 12 weeks, or if ineligible 
for PegIFN, sofosbuvir plus RBV for 24 weeks. Genotype 2 is 
treated with sofosbuvir plus RBV for 12 weeks, and genotype 
3 has the same treatment extended to 24 weeks. Genotype 4 
is treated with sofosbuvir plus Peg!FN and RBV for 12 weeks. 
Sofosbuvir is the first drug in its class and the first drug that 
does not necessarily require concomitant use of Peg!FN for 
the treatment of chronic HCV infection.6 
Review of Clinical Trials 
Several clinical trials have evaluated the safety and efficacy 
of these two new medications. One of the clinical trials evalu-
ated by the FDA in considering the approval of simeprevir 
was the ASPIRE triaJ.10 ASPIRE was a phase Ilb, randomized, 
double-blind trial. This trial evaluated the safety and efficacy 
of simeprevir plus Peg!FN/RBV in comparison to PegIFN/ 
RBV alone in patients with HCV genotype 1 who have previ-
ously failed to respond to treatment with PeglFN/RBV. Four 
hundred sixty-two patients began the trial and were divided 
into seven groups. All groups received Peg!FN/RBV for 48 
weeks. Each group also received either 100 mg or 150 mg 
simeprevir once daily for 12, 24 or 48 weeks, or no simepre-
vir, designated as the control group. The primary end point 
of the study was the proportion of patients maintaining SVR 
at 24 weeks after end of treatment (SVR24). In the simepre-
vir groups, 60.6 to 80.0 percent of patients achieved SVR24 
compared to 22.7 percent of the control group, demonstrat-
ing efficacy of the addition of simeprevir over Peg!FN/RBV 
alone. In the 150 mg simeprevir groups, 72.9 percent of pa-
tients achieved SVR24 compared to 65.6 percent of patients 
in 100 mg simeprevir groups, supporting the choice of 
150 mg capsules. Duration of treatment with simeprevir 
showed no improvement in SVR24 rate beyond 12 weeks 
(68.2% in 12-week groups, 69.2% in 24-week groups and 
70.2% in 48-week groups) supporting the use of simeprevir 
for only 12 weeks. 
The ASPIRE trial further looked at the efficacy of simeprevir 
versus the control group in patients with prior null response, 
prior partial response and relapse to previous treatment 
with Peg!FN/RBV.10 In prior null response patients (patients 
that did not achieve SVR in previous treatment with PegIFN/ 
RBV), SVR24 rates were 37.5 to 58.8 percent in simeprevir 
groups versus 18.8 percent in control group. In prior partial 
response patients (patients that had reduced HCV RNA in 
previous treatment with Peg!FN/RBV but did not achieve 
SVR), SVR24 rates were 47.8 to 86.4 percent in simeprevir 
groups versus 8.7 percent in control group. In prior relapse 
patients (patients that achieved SVR at end of treatment 
(EOT) with Peg!FN/RBV but had detectable HCV RNA 24 
weeks later), SVR24 rates were 76.9 to 88.9 percent in 
simeprevir groups versus 37 percent in control group. This 
indicates potential efficacy in patients with prior treatment 
failure. The safety profile in simeprevir groups was similar to 
that of the control group (Peg!FN/RBV alone). All groups had 
similar total incidence of adverse events (AEs) and severe 
AEs, with fatigue, headache, pruritus, influenza-like illness 
and neutropenia most frequently reported. Groups treated 
with simeprevir had higher frequency of rash (26.5% versus 
18.2%) and pruritus (34.1% versus 16.7%) than Peg!FN/ 
RBV groups, although severity of these AEs was similar. 
Another clinical trial evaluating simeprevir was the PILLAR 
trial.11 PILLAR was a phase Ilb, randomized, double-blind 
trial that assessed the safety and efficacy of simeprevir plus 
Peg!FN/RBV in comparison to Peg!FN/RBV alone in treat-
ment-na'ive patients with HCV genotype 1. The trial began 
with 386 patients divided into five groups. All groups 
received Peg!FN/RBV for 48 weeks unless the patient was 
eligible to end all treatment at 24 weeks. Each group also 
received either 75 mg or 150 mg simeprevir once daily for 12 
or 24 weeks, or no simeprevir, designated as the control 
group. If a simeprevir-treated patient achieved rapid vi-
rologic response (RVR; defined by HCV RNA undetectable at 
week 4) and had undetectable HCV RNA at weeks 12, 16 and 
20, Peg!FN/RBV could be stopped at week 24 rather than 
finishing the full 48 weeks. The primary end point was the 
proportion of patients maintaining SVR at week 72 of the 
trial (SVR72), with treatment ending at week 48 or earlier. 
There was a statistically significant difference in SVR72 be-
tween the 150 mg, 12-week simeprevir group versus control 
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group (77.9% versus 64.9%, P<0.05) and between the 150 
mg, 24-week simeprevir group versus control group (84.8% 
versus 64.9%, p<0.05), indicating that the addition of 150 mg 
daily simeprevir leads to greater success in therapy than 
PegIFN/RBV alone. No differences in SVR rates were noted 
between different durations of simeprevir treatment. RVR 
was achieved by 68.0 to 75.6 percent of simeprevir patients 
versus 5.2 percent of patients in the control group. Of sime-
previr-treated patients, 79.2 to 86.1 percent were eligible to 
complete all treatment at week 24. This is significant because 
it allowed these patients to cut treatment duration in half, 
saving money, time and inconvenience. Adverse events and 
serious AEs were similar across all groups. The most fre-
quently reported AEs were fatigue, influenza-like illness, pru-
ritus, headache and nausea, typically associated with 
PegIFN/RBV therapy. This trial did not show higher fre-
quency of rash and pruritus in simeprevir groups compared 
to PegIFN/RBValone. 
The FDA approval of the other new HCV treatment medica-
tion, sofosbuvir, was dependent on the FISSION trial and the 
POSITRON trial, among others.9,12 The FISSION trial was a 
phase III, randomized, open-label triaJ.12 This study evaluated 
the safety and efficacy of sofosbuvir plus RBV in comparison 
to PegIFN/RBV alone in treatment-naive patients with HCV 
genotype 2 or 3. At the beginning of the trial, 499 patients 
were randomized to receive either 400 mg sofosbuvir once 
daily plus RBV for 12 weeks or to receive Peg!FN/RBV for 24 
weeks. The primary end point was defined as the proportion 
of patients maintaining SVR at 12 weeks after EOT (SVR12). 
The primary end point was achieved in 67 percent of pa-
tients in the sofosbuvir/RBV group versus 67 percent in the 
PegIFN/RBV group, indicating that sofosbuvir/RBV therapy 
is not inferior in efficacy to PegIFN/RBV therapy. This is sig-
nificant in that it allows patients the option to receive treat-
ment with only oral medications. Patients with genotype 2 
achieved SVR12 in 97 percent of sofosbuvir/RBV group ver-
sus 78 percent of PegIFN/RBV group, supporting the efficacy 
of sofosbuvir/RBV therapy in genotype 2 HCV. Patients with 
genotype 3 HCV achieved SVR12 in 56 percent of sofosbuvir/ 
RBV group versus 63 percent of PegIFN/RBV group, indicat-
ing sofosbuvir /RBV for 12 weeks is not as effective as 
Peg!FN/RBV for 24 weeks in these patients. The FDA recom-
mends using sofosbuvir/RBV for 24 weeks (not 12 weeks) in 
patients with genotype 3.a Adverse events in this trial oc-
curred more frequently in PegIFN/RBV group than the sofos-
buvir /RBV group, and serious AEs were low among all 
groups. The most common AEs in all groups were fatigue, 
headache, nausea and insomnia.12 
Another clinical trial used by the FDA in consideration of so-
fosbuvir was the POSITRON trial. 9 POSITRON was a phase III, 
randomized, double-blinded trial. This trial evaluated the 
safety and efficacy of sofosbuvir /RBV compared to RBV 
alone in patients with HCV genotype 2 or 3 unable to take 
PegIFN. The trial began with 278 patients randomized to 
receive RBV and sofosbuvir 400 mg once daily for 12 weeks 
or to receive RBV and placebo for 12 weeks. The primary end 
point was SVR12. The primary end point was achieved in 78 
percent of sofosbuvir/RBV group versus 0 percent of RBV 
group. At EOT (12 weeks prior to this measurement), 100 
percent of sofosbuvir/RBV group versus 0 percent of RBV 
group had achieved SVR. This difference in SVR in the sofos-
buvir /RBV group was due to viral relapse after EOT. All cases 
of relapse that were reported occurred within 12 weeks after 
EOT, with no new cases ofrelapse reported between 12 to 24 
weeks after EOT. Treatment with sofosbuvir /RBV led to 
SVR12 in 93 percent of patients with HCV genotype 2 versus 
61 percent of patients with HCV genotype 3. Adverse events 
occurred more frequently in the sofosbuvir /RBV group than 
the RBV group, particularly fatigue, insomnia and anemia. 
The rate of AEs was overall low in both groups. The rate of 
serious AEs was similar between the two groups. Although 
the use of RBV alone is not a valid treatment option for the 
treatment of chronic HCV, giving the impression that this 
study is invalid, treatment with RBV alone may be the only 
option for patients who cannot tolerate PegIFN, especially in 
patients with non-genotype 1 HCV infection. This study sup-
ports the idea that treatment with sofosbuvir /RBV has better 
efficacy for patients with genotype 2 and 3 than RBV alone.9 
Pharmacists' Impact 
A look at the new medications' AEs and drug interactions can 
help a health care provider decide if these new medications 
would be right for his or her patient. Pharmacists can help 
counsel on the new drugs' adverse reactions, helping to en-
sure a safe introduction of these new medications. 
There are two major AEs with simeprevir: teratogenicity and 
sun sensitivity. Male and female patients taking simeprevir 
with RBV must use two forms of birth control while on the 
therapy and for six months after discontinuation.24 Female 
patients must be monitored monthly via pregnancy tests. 
Severe rashes may develop with simeprevir. These rashes 
occur with sun exposure and usually develop within the first 
four weeks of treatment. Patients should be encouraged to 
contact a health care provider if any sort of redness, rash or 
conjunctivitis occurs. Severe cases may require hospitaliza-
tion, so patients should be urged to wear sunscreen and pro-
tective clothing (such as hats) if they are going to be outside 
for long periods of time. As it contains a sulfonamide moiety, 
simeprevir should be used with caution in those patients 
with sulfa allergies. Simeprevir is contraindicated with vari-
ous medications ranging from over-the-counter supplements 
such as St. John's Wort to prescription hypertension medica-
tions. Patients should provide health care providers with a 
complete drug list, and pharmacists should monitor use of 
these contraindicated medications in patients taking sime-
previr. 
Similar to simeprevir, sofosbuvir requires two forms of birth 
control and pregnancy monitoring due to use with RBV, 
along with two negative pregnancy tests prior to beginning 
therapy. 7 Other sofosbuvir side effects include central nerv-
ous system effects such as depression, insomnia and nausea 
with headache and fatigue being the most common. Abnor-
malities in lab values including bilirubin, creatinine kinase, 
and lipases were also seen in patients taking sofosbuvir. The 
main drug interaction involved in sofosbuvir use is seen in 
potent intestinal P-glycoprotein inducers such as St. John's 
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Wort or rifampicin. These medications can alter the concen-
trations of sofosbuvir; therefore, their concurrent use is dis-
couraged. 
Neither of the medications has recommended renal or he-
patic dosing adjustments at this time, due to insufficient evi-
dence in these patient populations,7.B Each therapy is to be 
given over 12 weeks (with the exception of sofosbuvir in 
genotype 3), while monitoring different levels for dosing ad-
justments. Hemoglobin levels should be monitored with use 
of sofosbuvir due to ribavirin co-administration.a In patients 
with no history of cardiac disease, it is recommended that 
ribavirin be reduced to 600 mg/day with hemoglobin levels 
less than 10 g/dL and discontinued with levels less than 
8.5 g/dL. In patients with a history of stable cardiac disease, 
ribavirin levels should be reduced with any drop in hemoglo-
bin levels of over 2 g/dL over a four-week period or discon-
tinued if hemoglobin levels drop below 12 g/dL. Hepatitis C 
virus RNA levels are monitored with use of simeprevir.2s It is 
recommended to discontinue simeprevir, as well as Peg!FN 
and RBV, if HCV RNA levels reach 25 IU/mL or greater at any 
point during the therapy duration. 
Cost should be considered when weighing risks versus bene-
fits of these therapies. Both therapies have gained media at-
tention for their cost, many noting that these medications 
should be saved for those with severe cases of hepatitis c .26 
Simeprevir's 12 week therapy runs at $66,360, while sofos-
buvir is priced at $84,000.21,2a 
Place in Therapy 
The American Association for the Study of Liver Diseases 
(AASLD) provides working guidelines for the treatment of 
HCV infection that expound upon the place in therapy for 
these two new medications.29 Because these medications 
were approved relatively recently, the AASLD has created 
web-based 2014 guidelines that are continuously being 
modified as new data become available. In general, the 
AASLD 2014 guidelines recommend the use of sofosbuvir 
with RBV as first-line treatment in nearly all patients 
(treatment-naive and treatment-experienced patients with 
genotype 1 through 6), also including Peg!FN when appropri-
ate. The guidelines find sofosbuvir with RBV to have the best 
balance of high efficacy and AEs. Simeprevir with RBV / 
PegIFN is listed by the AASLD as an alternative regimen for 
treating genotype 1 and 4 (despite lack of FDA approval for 
use in genotype 4). The AASLD guidelines no longer recom-
mend the use RBV /PegIFN alone for nearly all patients, 
claiming that therapy with RBV /Peg!FN alone is inferior to 
the addition of sofosbuvir or simeprevir, due to lower effi-
cacy, higher rate of serious AEs, and longer treatment dura-
tion when RBV /Peg!FN is used alone. The guidelines prefer 
simeprevir over telaprevir and boceprevir, claiming com-
paratively lower efficacy, lower tolerability, and higher pill 
burden for telaprevir and boceprevir. Sofosbuvir and sime-
previr may be used more prominently for the treatment of 
HCV infection as these guidelines are finalized. 
Conclusion 
Hepatitis C virus is one of the most common blood-borne 
pathogens and can lead to serious long-term complications.1 
Simeprevir and sofosbuvir have been shown to be effective 
and safe in multiple studies for the treatment of chronic HCV 
infection in both treatment-naive and treatment-experienced 
patients.7,8 Simeprevir is approved for the treatment of geno-
type 1 HCV and requires concurrent RBV and PeglFN.7 Sofos-
buvir can treat genotype 1 through 4 HCV with concurrent 
RBV and sometimes PegIFN.a The side effect profile, drug 
interactions and cost of each of these new medications must 
be weighed against the potential benefit to the patient in 
treating chronic HCV infection. 
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